Durata Therapeutics, Inc. Release: New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial Pathogens Presented at the 23rd Annual ECCMID Meeting

Published: Apr 29, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced data from surveillance results of its lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSSI). The data, presented at the 23rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), demonstrate that in vitro potency of dalbavancin remains consistent with earlier surveillance reports.

Help employers find you! Check out all the jobs and post your resume.

Back to news